Adagene Will Present Interim Results of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) In Combination With Pembrolizumab In MSS CRC At American Society of Clinical Oncology 2024 Gastrointestinal Cancers Symposium
Author: Benzinga Newsdesk | January 04, 2024 06:03am